Flagship Ventures Fund V, L.P. 13D and 13G filings for Sigilon Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-14 4:36 pm Sale | 2023-12-31 | 13G | Sigilon Therapeutics, Inc. SGTX | Flagship Ventures Fund V, L.P. | 0 0.000% | -797,721 (Position Closed) | Filing |
| 2021-02-16 5:06 pm Purchase | 2020-12-31 | 13G | Sigilon Therapeutics, Inc. SGTX | Flagship Ventures Fund V, L.P. | 797,721 33.200% | 797,721 (New Position) | Filing |